OASIS trial: Ocriplasmin improves VMA resolution over long term

Ocriplasmin improved resolution of symptomatic vitreomacular adhesion, according to 2-year results of the OASIS trial.The phase 3b randomized, sham-controlled, double-masked, multicenter clinical trial included 220 patients; 146 patients received intravitreal Jetrea 0.125 mg (ocriplasmin, ThromboGenics), and 74 patients received a sham injection. Patients were evaluated at 12 visits over 24 months.